



Prelude Therapeutics to Participate in Barclays Global Healthcare Conference

February 29, 2024 9:05 PM EST

WILMINGTON, Del., Feb. 29, 2024 (GLOBE NEWSWIRE) -- [Prelude Therapeutics Incorporated](#) (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in the Barclays Global Healthcare Conference in Miami, March 12-14, 2024.

On Wednesday, March 13, at 3:05 p.m. ET, Kris Vaddi, Ph.D., Chief Executive Officer of Prelude, and Jane Huang, M.D., President and Chief Medical Officer, will participate in a fireside chat, hosted by Barclays.

A live webcast of the fireside chat can be accessed [here](#) and on the Company's website under [Events and Presentations](#). The recording will be archived and available on the Company's website for 90 days.

About Prelude Therapeutics

Prelude Therapeutics is a clinical-stage precision oncology company developing innovative drug candidates targeting critical cancer cell pathways. The Company's diverse pipeline is comprised of highly differentiated, potentially best-in-class proprietary small molecule compounds aimed at addressing clinically validated pathways for cancers with selectable underserved patients. Prelude's pipeline includes three candidates currently in clinical development: an IV administered, potent and highly selective SMARCA2 degrader, PRT3789, a preclinical oral SMARCA2 selective degrader, PRT7732, a potent and highly selective CDK9 inhibitor, PRT2527, and a next generation CDK4/6 inhibitor, PRT3645.

For more information, visit our [website](#) and follow us on [LinkedIn](#).

Investor Contact:

Lindsey Trickett
Vice President, Investor Relations
240.543.7970
ltrickett@preludetx.com

Media Contact:

Helen Shik
Shik Communications
617.510.4373
Helen@ShikCommunications.com